Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Apply
SLS009
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step